BRAF and thyroid gland carcinoma: BCPAP and KTC-1 thyroid cancer cell lines with the BRAF (V600E) mutation were used to examine the effects of increasing concentrations of MnTnBuOE-2-PyP on cell growth, using a clonogenic assay.